Search
ZELBORAF 240 MG, Comprimé pelliculé
Details
| --- | Description |
|---|---|
| Pack | Boite de 56 |
| Strength (Dosage) | 240 MG |
| Laboratory | ROCHE S.A |
| Ingredients | Vémurafénib |
| Therapeutic class | Antinéoplasique, inhibiteur de la sérine-thréonine kinase BRAF |
| ATC code | L01XE15 |
| PPH | $1,472.40 |
| PPV | $1,501.00 |
| Refundable | No |
| Refund base | $0.00 |
| Refund rate | $0.00 |
| Table | A |
| Marketing status | Commercialized |
| Type | Medication |
| Uses | Le vemurafenib est indiqué en monothérapie dans le traitement des patients adultes atteints d’un mélanome non résécable ou métastatique porteur d’une mutation BRAF V600. |
| Warnings | |
| Dosage | |
| Avoid | |
| Side effects | |
| Interactions |
Medications from the same laboratory
Disclaimer
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
Report a problem